The combination of the PARP inhibitor olaparib and the PD-1 inhibitor pembrolizumab showed initial antitumor activity with no new safety signals in a molecularly matched, tumor-agnostic trial, ...

Combining Lynparza (olaparib) and Keytruda (pembrolizumab) showed antitumor activity in multiple cancer types, particularly those with BRCA1/2 ...